Paul Badawi Sells 23,637 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 23,637 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $4.15, for a total transaction of $98,093.55. Following the transaction, the chief executive officer owned 5,986,943 shares in the company, valued at approximately $24,845,813.45. This trade represents a 0.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sight Sciences Price Performance

Shares of NASDAQ SGHT traded down $0.09 during midday trading on Thursday, reaching $3.43. The stock had a trading volume of 81,120 shares, compared to its average volume of 210,446. The company has a market capitalization of $177.32 million, a price-to-earnings ratio of -3.50 and a beta of 2.47. The stock has a 50-day moving average of $3.73 and a 200-day moving average of $3.14. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.51, a quick ratio of 9.99 and a current ratio of 10.47.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The company had revenue of $17.51 million during the quarter, compared to analysts' expectations of $16.51 million. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. As a group, research analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

SGHT has been the topic of several recent research reports. Piper Sandler reiterated a "neutral" rating and issued a $4.00 price target (up from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 28th. Lake Street Capital increased their price target on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research report on Friday, May 9th. Citigroup reiterated a "neutral" rating and issued a $3.60 price target (up from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $4.10.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors have recently bought and sold shares of SGHT. ProShare Advisors LLC bought a new position in Sight Sciences during the fourth quarter valued at $36,000. Dynamic Technology Lab Private Ltd bought a new position in Sight Sciences during the fourth quarter valued at $40,000. WealthTrust Asset Management LLC bought a new position in Sight Sciences during the fourth quarter valued at $48,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sight Sciences during the fourth quarter valued at $50,000. Finally, Wells Fargo & Company MN lifted its position in Sight Sciences by 53.4% during the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock valued at $60,000 after purchasing an additional 5,781 shares during the last quarter. Institutional investors own 55.51% of the company's stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.